FRDJ et Lilly Canada financent à l'UCB des recherches susceptibles de permettre aux personnes ayant le diabète de type 1 de produire leur propre insuline
07 févr. 2017 11h39 HE
|
JDRF/FRDJ
VANCOUVER, BC--(Marketwired - 7 février 2017) - FRDJ et Lilly Canada ont attribué une bourse de recherche postdoctorale de 60 000 $CA à une chercheuse prometteuse, la Dre Cara Ellis, boursière...
JDRF & Lilly Canada fund UBC research that could allow people with type 1 diabetes to produce their own insulin
07 févr. 2017 11h38 HE
|
JDRF/FRDJ
VANCOUVER, BC--(Marketwired - February 07, 2017) - JDRF and Lilly Canada have awarded a post-doctoral fellowship grant of CAN$60,000 to promising researcher Dr. Cara Ellis, a post-doctoral fellow...
Actinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma
07 févr. 2017 08h00 HE
|
Actinium Pharmaceuticals
- Phase 1 trial will evaluate Actimab-M in treating patients with multiple myeloma who are unresponsive to currently available therapies - Clinical trial initiated at Texas Oncology - Baylor Charles...
Actinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative Neoplasms
24 janv. 2017 07h00 HE
|
Actinium Pharmaceuticals
- Dr. Berger’s presentation included in session on Immunotherapy and Bispecific Inhibitors in Acute Leukemia - Two day event will be attended by transplant physicians and hematologists...
Actinium Announces Participation in Three Upcoming Hematology Events
20 janv. 2017 07h00 HE
|
Actinium Pharmaceuticals
Representatives from Actinium will attend to promote awareness among attending physicians and health professionals on Iomab-B and the SIERRA trial NEW YORK, Jan. 20, 2017 (GLOBE NEWSWIRE) --...
Actinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical Officer
18 janv. 2017 08h00 HE
|
Actinium Pharmaceuticals
Dr. Berger brings 20 years of drug development experience highlighted by the FDA approvals of Mylotarg® for acute myeloid leukemia, the only drug approved in AML in several decades, and Tykerb® for...
Actinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 Conference
10 janv. 2017 07h00 HE
|
Actinium Pharmaceuticals
NEW YORK, Jan. 10, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 Conference
04 janv. 2017 07h00 HE
|
Actinium Pharmaceuticals
NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Pharmaceuticals Appoints Jeannine Larrieux, Ph.D. as Director of Analytical Development to Support BLA and IND Enabling Analytical Studies for Current and Future Clinical Programs
19 déc. 2016 07h00 HE
|
Actinium Pharmaceuticals
- Dr. Larrieux brings significant experience managing analytical development quality control of immunotherapies to treat cancer and small molecule therapies at pharmaceutical and biotechnology...
Actinium Pharmaceuticals Announces Submission of EU Orphan Designation Application for Actimab-A
13 déc. 2016 07h00 HE
|
Actinium Pharmaceuticals
- Actimab-A has received Orphan Drug Designation in the U.S. - Orphan Designation in the EU can result in regulatory assistance, reduced fees and 10 years of market exclusivity ...